You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

93 search results for: chronic inflammation

Role of Type 2 <b>Inflammation</b> in Skin Barrier Disruption and Itch

expert video

Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

4 min

Dermatology

In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses how type 2 inflammation contributes to epidermal barrier dysfunction and chronic itch in AD

Type 2 <b>Inflammation</b> Within Skin Tissue in AD

expert video

Type 2 Inflammation Within Skin Tissue in AD

4 min

Dermatology

In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Stephan Weidinger discusses how type 2 inflammation contributes to epidermal barrier dysfunction, perivascular infiltration and plasma protein leakage, and chronic itch in AD.

Podcast

ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

20 min

Dermatology

This podcast episode looks at the epidemiology, clinical presentation and classification of atopic dermatitis of the hand and feet and the impact it has on patients' quality of life.

expert video

Impact of Exacerbations in COPD

2 min

Type 2 Inflammation

Dr. Stephanie Christenson discusses the association between COPD exacerbations and the increased risks of morbidity and mortality

expert video

Exacerbations Lead to Worsening Lung Function

2 min

Type 2 Inflammation

Dr. Mario Castro discusses how COPD exacerbations can predict future exacerbations and lead to progressive lung function loss in COPD patients.

expert video

A brief overview of the pathophysiology of PN

5 min

Dermatology

Dr. Chovatiya explains that PN is primarily a chronic itch disease with a complex pathophysiology involving neuronal changes, type 2 inflammation, and fibrotic skin processes, affecting patients' overall well-being.

Podcast

ADVENT On Air | Common Drivers of Type 2 Inflammatory Diseases

15 min

Type 2 Inflammation

Profs. Klaus Rabe and Stephan Weidinger discuss shared and unique features of type 2 inflammatory diseases and the benefits of multidisciplinary care

expert video

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

5 min

Dermatology

Dr. Oscar Palomares explains that IL-4 and IL-13 are crucial cytokines in type 2 inflammation, playing both unique and overlapping roles, including T cell expansion and contributing to clinical symptoms in chronic diseases.

videoanimation

The Pathophysiology of Prurigo Nodularis

5 min

Dermatology

An infographic exploring the pathophysiology of prurigo nodularis and the role of type 2 inflammation.

expert video

Multidisciplinary Partnership for Type 2 Inflammatory Diseases

18 min

Type 2 Inflammation

Drs. Thomas Casale, Mario Castro and Profs. Peter Hellings, Ian Pavord, Ulrike von Arnim, and Stephan Weidinger discuss multidisciplinary care

expert video

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

60 min

Dermatology

This full video presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida features Dr. Eric Simpson, Dr. Shawn Kwatra, Dr. Jason Hawkes and Dr. Victoria Werth. The faculty present the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).

UCARE 2023: Targeting Type 2 <b>Inflammation</b> in CSU – Clinical and Mechanistic Implications

expert video

UCARE 2023: Targeting Type 2 Inflammation in CSU – Clinical and Mechanistic Implications

34 min

Dermatology

Exploring the role of type 2 inflammation and the neuroimmune axis in CSU, and how emerging therapeutics are targeting key molecules in these pathways.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BrazilChange country/region